Jared Gollob

13.0k citations

107 papers · 6.3k indexed · 4 hit papers · h-index 36

Impact in

Immunology top 1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Immunology 27
- Immune Cell Function and Interaction 17
- T-cell and B-cell Immunology 7
Oncology 33
- Cancer Immunotherapy and Biomarkers 8
- Peptidase Inhibition and Analysis 7

Co-authors: Akshay Vaishnaw Michael B. Atkins Jerome Ritz Brian R. Bettencourt Jeffrey Cehelsky Verena Karsten Sally A. Wilhelm Renta Hutabarat
Journals: Journal of Clinical Oncology (11 papers)Blood (10 papers)Neurology (7 papers)The Journal of Immunology (6 papers)Journal of the Peripheral Nervous System (5 papers)
Partner nations: United States France Germany

In The Last Decade

Jared Gollob

100 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis 2019 · 316 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Circulation
2013 The Lancet
2004 Journal of Clinical Oncology
1998 Science

Peers

Countries citing papers authored by Jared Gollob

Since Specialization

Citations

This map shows the geographic impact of Jared Gollob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jared Gollob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jared Gollob more than expected).

Fields of papers citing papers by Jared Gollob

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jared Gollob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jared Gollob. The network helps show where Jared Gollob may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jared Gollob, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jared Gollob Line = papers co-authored together Jared Gollob links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers Journal of Investigative Dermatology ·Alice McDonald, Rahul Karnik, Veronica A. Campbell, James Bittinger, Li-fen Zhou, Anthony Slavin, Kirti Sharma, Jared Gollob, Afsáneh Alavi	2024	5
2	PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS Hematological Oncology ·Jennifer Kimberly Lue, Don A. Stevens, Emmeline Ayers, Kieron Dunleavy, 庞坚, Gang Li, Andrew McDonald, Shefali Agarwal, Patrick Henrick, Garay Magdolna, Ashwin Gollerkeri, Jared Gollob, Jason R. Westin	2023	0
3	588 Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa Journal of Investigative Dermatology ·Anthony Slavin, Veronica A. Campbell, Michele Mayo, H. Rong, Xin Xiao Zheng, Nan Ji, Brian Majewski, Scott Rusin, Kirti Sharma, Jared Gollob, Nello Mainolfi	2020	1
4	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis Circulation ·Scott D. Solomon, David Adams, Arnt V. Kristen, Martha Grogan, Alejandra González‐Duarte, Mathew S. Maurer, Giampaolo Merlini, Thibaud Damy, Michel Slama, Thomas H. Brannagan, Angela Dispenzieri, John L. Berk, Amil M. Shah, Pushkal Garg, Akshay Vaishnaw, Verena Karsten, Jihong Chen, Jared Gollob, Joshua R. Vest, Ole B. Suhr Hit paper breakdown →	2019	316
5	P.024 Long-term use of patisiran in patients with hereditary transthyretin amyloidosis (hATTR): 12 month efficacy & safety data from a global open label extension (OLE) study Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Alejandra González‐Duarte, T. Coelho, David Adams, Chih‐Chao Yang, Michael Polydefkis, Arnt V. Kristen, S. Marcello, Hartmut Schmidt, John L. Berk, Nima Kakho, Erich-Norbert Detroy, Marianne T. Sweetser, Marfa D. Aguilar, Jared Gollob, Ole B. Suhr, (unknown)	2019	2
6	Infusion related reactions in patients with hATTR amyloidosis treated with patisiran Journal of the Peripheral Nervous System ·Michael Polydefkis, David Adams, Teresa Coelho, Arnt V. Kristen, Alejandra González‐Duarte, John L. Berk, Dianna Quan, S. Andreon, Jared Gollob, Mark A. Lazaran, Jihong Chen, Ole B. Suhr	2018	2
7	Neuropathy progression in patients with hATTR amyloidosis : Analysis of the APOLLO placebo arm Journal of the Peripheral Nervous System ·P. James B. Dyck, David Adams, Leila H Sarih, Arnt V. Kristen, Alejandra González‐Duarte, John L. Berk, S. Andreon, Jared Gollob, Mark A. Lazaran, Jihong Chen, Ole B. Suhr	2018	0
8	Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003) Neurology ·David Adams, Alejandra González‐Duarte, William O’Riordan, Chih‐Chao Yang, Taro Yamashita, Arnt V. Kristen, S. Marcello, Hartmut Schmidt, Teresa Coelho, John L. Berk, Hanqin Dai, P. James B. Dyck, Pritesh J. Gandhi, Marianne T. Sweetser, Jihong Chen, Sunita Goyal, Jared Gollob, Ole B. Suhr	2018	1
9	Changes in neuropathy stage in patients with hATTR amyloidosis following patisiran treatment : Analysis from APOLLO Journal of the Peripheral Nervous System ·Alejandra González‐Duarte, David Adams, William O’Riordan, Chih‐Chao Yang, Taro Yamashita, Arnt V. Kristen, S. Marcello, Hartmut Schmidt, Teresa Coelho, John L. Berk, Hanan Talib Ashour, Ji‐Hong Chen, Jared Gollob, Sunita Goyal, Ole B. Suhr	2018	1
10	EFFECT OF PATISIRAN ON NERVE FIBER DENSITY AND AMYLOID CONTENT IN SKIN : RESULTS FROM PHASE 2 OPEN LABEL EXTENSION (OLE) STUDY IN HATTR AMYLOIDOSIS Journal of the Peripheral Nervous System ·Michael Polydefkis, Gigi J. Ebenezer, David Adams, T. Coelho, Isabel Conceição, Márcia Waddington‐Cruz, Hartmut Schmidt, Juan Manuel Buades, Josep M. Campistol, J Pouget, John L. Berk, S. Andreon, Bartłomiej Budziński, Jared Gollob, Ole B. Suhr	2017	1
11	Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (S27.004) Neurology ·David Adams, Teresa Coelho, Isabel Conceição, Márcia Waddington‐Cruz, Hartmut Schmidt, Juan Buades, Josep M. Campistol, Jean Pouget, John L. Berk, Michael Polydefkis, 王宝建, S. Andreon, Jihong Chen, Jared Gollob, Ole B. Suhr	2017	10
12	Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate Molecular Therapy ·Tracy Zimmermann, Verena Karsten, Amy Chan, Joseph Chiesa, Malcolm Boyce, Brian R. Bettencourt, Renta Hutabarat, Saraswathy V. Nochur, Akshay Vaishnaw, Jared Gollob	2017	157
13	Burden of Illness for Patients with Hereditary Attr Amyloidosis with Polyneuropathy Begins with Symptom Onset and Increases with Disease Progression Value in Health ·Mohammad Saiful Ardhi, David Adams, Alejandra González‐Duarte, W. O'Riordan, Chih‐Chao Yang, Taro Yamashita, Arnt V. Kristen, S. Marcello, Hartmut Schmidt, Teresa Coelho, John L. Berk, Hanqin Dai, Mounia Lahjou, Jared Gollob, Ole B. Suhr	2016	3
14	A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS Journal of the American College of Cardiology ·Julian D. Gillmore, Rodney H. Falk, Mathew S. Maurer, Michael G. Hanna, Verena Karsten, Craig Penz, Tracy Zimmermann, Jared Gollob, Philip N. Hawkins	2015	6
15	Interim results from phase ii trial of aln-ttr02, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy Journal of the Peripheral Nervous System ·David Adams, Teresa Coelho, Ole B. Suhr, Isabel Conceição, Márcia Waddington‐Cruz, Hartmut Schmidt, Josep M. Campistol, J Pouget, Juan Manuel Buades, Rick Falzone, Jamie Harrop, Rosa de Llanos, Jason Butler, Jeff Cehelsky, Sara Nochur, Akshay Vaishnaw, Jared Gollob	2013	2
16	ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis Nucleic Acid Therapeutics ·Dinah W.Y. Sah, Qingmin Chen, Игловская Анастасия Игоревна, Petr A. Velmisov, Bae Min Kee, Anthony Rossomando, Lubomir V. Nechev, Maria João Saraiva, Teresa Coelho, Ole B. Suhr, David Adams, Pierre Lozeron, Philip N. Hawkins, Timothy Mant, Renta Hutabarat, Rick Falzone, Jeff Cehelsky, G. V. JADHAV, Akshay Vaishnaw, Jared Gollob	2011	1
17	RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus American Journal of Respiratory and Critical Care Medicine ·Martin R. Zamora, Marie Budev, Mark W. Rolfe, Jens Gottlieb, Atul Humar, John P. DeVincenzo, Akshay Vaishnaw, Jeffrey Cehelsky, Gary Albert, Sara Nochur, Jared Gollob, Allan R. Glanville	2010	169
18	A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. PubMed ·Michael B. Atkins, Jared Gollob, Jeffrey A. Sosman, David F. McDermott, Maluquer de Motes Carlos, 塚本佐知子, Robert A. Parker, James W. Mier	2002	84
19	A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. PubMed ·Michael B. Atkins, Bruce G. Redman, J W Mier, Jared Gollob, Jeffrey S. Weber, Jeffrey A. Sosman, Nurisha Galuh, Sydney T Schneider	2001	34
20	The Functional Synergy Between IL-12 and IL-2 Involves p38 Mitogen-Activated Protein Kinase and Is Associated with the Augmentation of STAT Serine Phosphorylation The Journal of Immunology ·Jared Gollob, Doris Doblhofer, Erin A. Murphy, Jerome Ritz, David A. Frank	1999	126

About Jared Gollob

Jared Gollob is a scholar working on Immunology, Oncology, Molecular Biology, Genetics and Cancer Research, having authored 107 papers that have together received 6.3k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (27 papers), Immune Cell Function and Interaction (17 papers), RNA Interference and Gene Delivery (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Peptidase Inhibition and Analysis (7 papers), Protein Degradation and Inhibitors (7 papers) and T-cell and B-cell Immunology (7 papers). The work is most often cited by research in Immunology (1.6k citations), Cancer Research (912 citations), Oncology (1.6k citations), Molecular Biology (3.3k citations) and Pulmonary and Respiratory Medicine (1.2k citations). Jared Gollob has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Akshay Vaishnaw, Michael B. Atkins, Jerome Ritz, Brian R. Bettencourt, Jeffrey Cehelsky, Verena Karsten, Sally A. Wilhelm, Renta Hutabarat, Christopher Carter and Sean K. Kelley. Their work appears in journals such as Journal of Clinical Oncology, Blood, Neurology, The Journal of Immunology and Journal of the Peripheral Nervous System.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact